Published in Acta Haematol on March 17, 2010
Soft-tissue sarcomas in adults. N Engl J Med (2005) 5.97
A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia. Nat Genet (2008) 4.37
Common variants at 2q37.3, 8q24.21, 15q21.3 and 16q24.1 influence chronic lymphocytic leukemia risk. Nat Genet (2010) 2.45
Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis. Br J Haematol (2009) 2.10
Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial. J Clin Oncol (2011) 1.71
Prognostic features of splenic lymphoma with villous lymphocytes: a report on 129 patients. Br J Haematol (2003) 1.66
Inherited predisposition to CLL is detectable as subclinical monoclonal B-lymphocyte expansion. Blood (2002) 1.52
Insight into the molecular pathogenesis of hairy cell leukaemia, hairy cell leukaemia variant and splenic marginal zone lymphoma, provided by the analysis of their IGH rearrangements and somatic hypermutation patterns. Br J Haematol (2009) 1.48
Prognostic factors identified three risk groups in the LRF CLL4 trial, independent of treatment allocation. Haematologica (2010) 1.47
The t(14;19)(q32;q13)-positive small B-cell leukaemia: a clinicopathologic and cytogenetic study of seven cases. Br J Haematol (2006) 1.46
Lessons from a case of T-cell large granular lymphocytic leukaemia suggesting that immunomodulatory therapy is more effective than intensive treatment. Leuk Res (2005) 1.45
A high-density SNP genomewide linkage scan for chronic lymphocytic leukemia-susceptibility loci. Am J Hum Genet (2005) 1.43
Retroperitoneal tumours: review of management. Ann R Coll Surg Engl (2011) 1.42
A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease. Blood (2003) 1.41
CD34 and CD117 are overexpressed in AML and may be valuable to detect minimal residual disease. Leuk Res (2002) 1.41
Biallelic ATM inactivation significantly reduces survival in patients treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 trial. J Clin Oncol (2012) 1.36
Does the two-week rule pathway improve the diagnosis of soft tissue sarcoma? A retrospective review of referral patterns and outcomes over five years in a regional sarcoma centre. Ann R Coll Surg Engl (2010) 1.28
Common variation at 6p21.31 (BAK1) influences the risk of chronic lymphocytic leukemia. Blood (2012) 1.26
Aggressive fibromatosis: MRI features with pathologic correlation. AJR Am J Roentgenol (2006) 1.23
High dose methylprednisolone can induce remissions in CLL patients with p53 abnormalities. Ann Hematol (2003) 1.22
Prognosis of lymph node metastasis in soft tissue sarcoma. Ann Surg Oncol (2004) 1.19
A gene expression signature associated with metastatic outcome in human leiomyosarcomas. Cancer Res (2004) 1.18
Transmission of donor melanoma by organ transplantation. Lancet Oncol (2010) 1.15
Primary bone marrow lymphoma: an uncommon extranodal presentation of aggressive non-hodgkin lymphomas. Am J Surg Pathol (2012) 1.15
Genome sequencing of mucosal melanomas reveals that they are driven by distinct mechanisms from cutaneous melanoma. J Pathol (2013) 1.12
Adult rhabdomyosarcoma: cross-sectional imaging findings including histopathologic correlation. AJR Am J Roentgenol (2007) 1.12
Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemia. Br J Haematol (2012) 1.08
Alemtuzumab therapy in T-cell prolymphocytic leukemia: comparing efficacy in a series treated intravenously and a study piloting the subcutaneous route. Blood (2011) 1.04
Delineation of the minimal region of loss at 13q14 in multiple myeloma. Genes Chromosomes Cancer (2003) 1.04
Fine-scale mapping of the 6p25.3 chronic lymphocytic leukaemia susceptibility locus. Hum Mol Genet (2010) 1.02
T-cell large granular lymphocyte leukemia: A report on the treatment of 29 patients and a review of the literature. Cancer (2006) 1.01
Long remissions in hairy cell leukemia with purine analogs: a report of 219 patients with a median follow-up of 12.5 years. Cancer (2005) 1.00
Gemcitabine, cisplatin and methylprednisolone for the treatment of patients with peripheral T-cell lymphoma: the Royal Marsden Hospital experience. Haematologica (2007) 1.00
Zeta-chain associated protein 70 and CD38 combined predict the time to first treatment in patients with chronic lymphocytic leukemia. Cancer (2005) 0.99
High dose methylprednisolone and rituximab is an effective therapy in advanced refractory chronic lymphocytic leukemia resistant to fludarabine therapy. Haematologica (2008) 0.99
The efficacy of alemtuzumab for refractory chronic lymphocytic leukemia in relation to cytogenetic abnormalities of p53. Haematologica (2005) 0.98
Malignancies confined to disused arteriovenous fistulae in renal transplant patients: an important differential diagnosis. Am J Nephrol (2011) 0.97
The diagnostic value of CD123 in B-cell disorders with hairy or villous lymphocytes. Haematologica (2004) 0.96
Stem cell transplantation after alemtuzumab in T-cell prolymphocytic leukaemia results in longer survival than after alemtuzumab alone: a multicentre retrospective study. Br J Haematol (2010) 0.96
Characterisation of TP53 abnormalities in chronic lymphocytic leukaemia. Hematol J (2004) 0.96
Amputation for soft-tissue sarcoma. Lancet Oncol (2003) 0.95
Ilioinguinal lymph node dissection for palpable metastatic melanoma to the groin. ANZ J Surg (2008) 0.95
Constitutive expression of the AP-1 transcription factors c-jun, junD, junB, and c-fos and the marginal zone B-cell transcription factor Notch2 in splenic marginal zone lymphoma. J Mol Diagn (2004) 0.95
The mutational burden of acral melanoma revealed by whole-genome sequencing and comparative analysis. Pigment Cell Melanoma Res (2014) 0.95
Isolated limb perfusion with melphalan and tumor necrosis factor alpha for advanced melanoma and soft-tissue sarcoma. Ann Surg Oncol (2007) 0.95
Hepatic subcapsular hematoma: two neonates with disparate presentations. Pediatr Neonatol (2012) 0.94
Combinations of ZAP-70, CD38 and IGHV mutational status as predictors of time to first treatment in CLL. Leuk Lymphoma (2008) 0.93
Isolated bone marrow involvement in diffuse large B cell lymphoma: a report of three cases with review of morphological, immunophenotypic and cytogenetic findings. Leuk Lymphoma (2004) 0.93
The radiological manifestations of intramuscular haemangiomas in adults: magnetic resonance imaging, computed tomography and ultrasound appearances. Skeletal Radiol (2007) 0.93
Deletion mapping on the long arm of chromosome 7 in splenic lymphoma with villous lymphocytes. Genes Chromosomes Cancer (2003) 0.92
Prolymphocytic leukemias. Semin Oncol (2006) 0.92
What does the medical profession mean by "standard of care?". J Clin Oncol (2009) 0.91
Sentinel lymph node biopsy in malignant melanoma. BMJ (2008) 0.91
ATM germline heterozygosity does not play a role in chronic lymphocytic leukemia initiation but influences rapid disease progression through loss of the remaining ATM allele. Haematologica (2011) 0.91
Insight into the pathogenesis of chronic lymphocytic leukemia (CLL) through analysis of IgVH gene usage and mutation status in familial CLL. Blood (2008) 0.91
Gastric necrosis in a patient with bulimia. Eur J Surg (2002) 0.91
Rituximab with pentostatin or cladribine: an effective combination treatment for hairy cell leukemia after disease recurrence. Leuk Lymphoma (2011) 0.91
ATM mutations are rare in familial chronic lymphocytic leukemia. Blood (2002) 0.91
Unusual case of leukemic mantle cell lymphoma with amplified CCND1/IGH fusion gene. Genes Chromosomes Cancer (2002) 0.90
Causation of chronic lymphocytic leukemia--insights from familial disease. Leuk Res (2003) 0.90
Intra-abdominal metastases from soft tissue sarcoma. J Surg Oncol (2004) 0.90
Alemtuzumab in T-cell lymphoproliferative disorders. Best Pract Res Clin Haematol (2006) 0.90
Relationship between glutathione S-transferase M1, T1, and P1 polymorphisms and chronic lymphocytic leukemia. Blood (2002) 0.89
Genetic variation in CXCR4 and risk of chronic lymphocytic leukemia. Blood (2009) 0.89
Translocation t(2;7)(p12;q21-22) with dysregulation of the CDK6 gene mapping to 7q21-22 in a non-Hodgkin's lymphoma with leukemia. Haematologica (2002) 0.89
A quality-of-life study in high-risk (thickness > = or 2 mm) cutaneous melanoma patients in a randomized trial of 1-cm versus 3-cm surgical excision margins. J Investig Dermatol Symp Proc (2004) 0.89
Sentinel lymph node biopsy: not yet standard of care for melanoma. BMJ (2004) 0.89
Drug cross-resistance and therapy-induced resistance in chronic lymphocytic leukaemia by an enhanced method of individualised tumour response testing. Br J Haematol (2009) 0.89
Splenic marginal zone lymphoma with villous lymphocytes shows on-going immunoglobulin gene mutations. Am J Pathol (2003) 0.88
Rituximab, used alone or in combination, is superior to other treatment modalities in splenic marginal zone lymphoma. Br J Haematol (2012) 0.88
Gene abnormalities in multiple myeloma; the relevance of TP53, MDM2, and CDKN2A. Haematologica (2003) 0.87
p53 and mdm2 in mantle cell lymphoma in leukemic phase. Haematologica (2002) 0.87
Prognostic false-positivity and cost-effectiveness in sentinel node biopsy in melanoma. Ann Surg Oncol (2009) 0.87
Freedom of expression or protectionism in the debate on sentinel node biopsy in melanoma. J Am Acad Dermatol (2009) 0.87
The feasibility of plerixafor as a second-line stem cell mobilizing agent in children. J Pediatr Hematol Oncol (2011) 0.87
Functional analysis of the ATM-p53-p21 pathway in the LRF CLL4 trial: blockade at the level of p21 is associated with short response duration. Clin Cancer Res (2012) 0.87
Sentinel-node biopsy in melanoma. N Engl J Med (2014) 0.87
Management of benign retroperitoneal schwannomas: a single-center experience. Am J Surg (2011) 0.86
Use of zidovudine and interferon alfa with chemotherapy improves survival in both acute and lymphoma subtypes of adult T-cell leukemia/lymphoma. J Clin Oncol (2011) 0.86
Alemtuzumab in T-cell malignancies. Med Oncol (2002) 0.85
CD38 expression as a prognostic indicator in chronic lymphocytic leukaemia. Hematol J (2004) 0.85
The role of rituximab in combination with pentostatin or cladribine for the treatment of recurrent/refractory hairy cell leukemia. Cancer (2007) 0.84
Diagnostic significance of CD20 and FMC7 expression in B-cell disorders. Am J Clin Pathol (2003) 0.84
Portsite recurrence after laparoscopy for staging of retroperitoneal sarcoma. Surg Laparosc Endosc Percutan Tech (2003) 0.84
Childhood near-tetraploid acute lymphoblastic leukemia: an EGIL study on 36 cases. Eur J Haematol (2010) 0.84
Splenic diffuse red pulp small B-cell lymphoma: revision of a series of cases reveals characteristic clinico-pathological features. Haematologica (2010) 0.84
Simplification of risk stratification for splenic marginal zone lymphoma: a point-based score for practical use. Leuk Lymphoma (2013) 0.84
MRI identified prognostic features of tumors in distal sigmoid, rectosigmoid, and upper rectum: treatment with radiotherapy and chemotherapy. Int J Radiat Oncol Biol Phys (2006) 0.83
Sentinel lymph node biopsy as the standard of care for cutaneous melanoma. Clin Adv Hematol Oncol (2007) 0.82
Severe liver dysfunction from hepatitis C virus reactivation following alemtuzumab treatment for chronic lymphocytic leukaemia. Br J Haematol (2009) 0.82
MTHFR polymorphisms and risk of chronic lymphocytic leukemia. Cancer Epidemiol Biomarkers Prev (2004) 0.82
Usefulness and limitations of Bayesian network model as a mortality risk assessment tool in sickle cell anemia. Am J Hematol (2009) 0.81
The P2X7 receptor gene A1513C polymorphism does not contribute to risk of familial or sporadic chronic lymphocytic leukemia. Cancer Epidemiol Biomarkers Prev (2004) 0.79
Clinical and biological diversity of splenic marginal zone lymphoma. Expert Rev Anticancer Ther (2009) 0.79